Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cevostamab Consolidation Post-BCMA CAR T in R/R Multiple Myeloma
NCT05801939Phase 2Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jul 2023
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cevostamab in multiple myeloma (MM), sponsored by University of Pennsylvania. Primary endpoint: Minimal Residual Disease-negative Complete Remission at 12 months. Started Jul 2023; status: active, not recruiting.
02
Drugs
cevostamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05801939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05801939.